Cancer Immunotherapy Advances

This cluster examines the effectiveness and mechanisms of various immunotherapy treatments across different cancers. Research highlights successful strategies for enhancing immune responses against tumors.

immunotherapy
cancer treatment
immune checkpoint inhibitors
survival rates
melanoma
clinical trials

91,416 papers

Parent topic: Cancer Research and Treatment

AI-assisted content · The overview, paper groupings, and influence analysis on this page are AI-generated. They are intended as a starting point for exploring the field and may contain inaccuracies. Report an error

Papers Over Time

19201930194019501960197019801990200020102020

Top Papers

Improved Survival With Ipilimumab In Patients With Metastatic Melanoma

2010 · 13,117 citations

Pembrolizumab Versus Chemotherapy For PD-L1–Positive Non–Small-Cell Lung Cancer

2017 · 7,026 citations

Improved Survival With Vemurafenib In Melanoma With BRAF V600E Mutation

2011 · 6,903 citations

Combined Nivolumab And Ipilimumab Or Monotherapy In Untreated Melanoma

2015 · 6,665 citations

Remdesivir For The Treatment Of Covid-19 — Final Report

2020 · 6,017 citations

PD-1 Blockade Induces Responses By Inhibiting Adaptive Immune Resistance

2014 · 5,596 citations

Pembrolizumab For The Treatment Of Non–Small-Cell Lung Cancer

2015 · 5,299 citations

Pembrolizumab Plus Chemotherapy In Metastatic Non–Small-Cell Lung Cancer

2018 · 5,096 citations

Pembrolizumab Versus Ipilimumab In Advanced Melanoma

2015 · 4,980 citations

Nivolumab In Previously Untreated Melanoma withoutBRAFMutation

2015 · 4,846 citations

Pembrolizumab Versus Docetaxel For Previously Treated, PD-L1-positive, Advanced Non-Small-Cell Lung Cancer (KEYNOTE-010): A Randomised Controlled Trial.

2016 · 4,714 citations

Pembrolizumab Versus Docetaxel For Previously Treated, PD-L1-positive, Advanced Non-Small-Cell Lung Cancer (KEYNOTE-010): A Randomised Controlled Trial

2016 · 4,532 citations

Axicabtagene Ciloleucel CAR T-Cell Therapy In Refractory Large B-Cell Lymphoma

2017 · 4,408 citations

Nivolumab For Recurrent Squamous-Cell Carcinoma Of The Head And Neck

2016 · 4,044 citations

Ipilimumab Plus Dacarbazine For Previously Untreated Metastatic Melanoma

2011 · 3,996 citations

The Future Of Immune Checkpoint Therapy

2015 · 3,918 citations

Nivolumab Plus Ipilimumab In Advanced Melanoma

2013 · 3,749 citations

Genetic Basis For Clinical Response To CTLA-4 Blockade In Melanoma

2014 · 3,696 citations

Immune-Related Adverse Events Associated With Immune Checkpoint Blockade

2018 · 3,380 citations

Nivolumab In Patients With Advanced Hepatocellular Carcinoma (CheckMate 040): An Open-Label, Non-Comparative, Phase 1/2 Dose Escalation And Expansion Trial

2017 · 3,183 citations